AUS
NZ
UK
CA
USA
IND
Headlines
- Institutional Ownership: Various hedge funds have increased their stakes in Bausch Health Companies, with institutional investors owning 78.65% of the company's stock.
- Financial Performance: Bausch Health recently reported a revenue increase of 12.2% year-over-year, with a quarterly EPS of $1.12, exceeding analysts' expectations.
Detailed Analysis
In a recent development, Merit Financial Group LLC has acquired a notable new stake in Bausch Health Companies Inc. (NYSE:BHC) during the fourth quarter, as reflected in their latest Form 13F filing with the Securities and Exchange Commission. Acquiring 28,245 shares valued at approximately $228,000, Merit Financial Group’s investment marks a significant move in the company’s strategic interest.
Other institutional investors have also altered their positions, including Mackenzie Financial Corp, which boosted its stake by 111% in the second quarter, owning 2,381,888 shares valued at $16,612,000. Likewise, LMR Partners LLP, Clearline Capital LP, Intact Investment Management Inc., and XTX Topco Ltd have bolstered their holdings in Bausch Health Companies across various quarters, collectively underscoring the confidence in the company’s steady performance.
Bausch Health Companies' stock commenced trading at $7.73 recently, sitting within a 52-week range that spans from a low of $3.96 to a high of $11.46, reflecting the stock's volatility across the year. With a market capitalization of $2.79 billion and a P/E ratio of -16.09, the company's stock performance continues to draw considerable attention from investors and financial analysts.
Recently, Bausch Health Companies announced its quarterly earnings, showcasing a robust financial performance with a reported earnings per share (EPS) of $1.12, surpassing analysts’ consensus estimates of $1.02. The firm reported revenue of $2.51 billion, outperforming the projected $2.42 billion and showcasing a 12.2% growth from the previous year.
Despite these encouraging earnings, the company experiences challenges with a negative net margin of 1.88% and a return on equity standing at a staggering negative 755.86%. Nevertheless, Bausch Health Companies remains optimistic, with equities research analysts forecasting an EPS of 3.73 for the current year.
Company Overview
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device enterprise in the United States and internationally. The company’s extensive portfolio spans various therapeutic areas including gastroenterology, dermatology, neurology, hepatology, and ophthalmology, offering a broad range of innovative health solutions across these domains.
As Bausch Health Companies continues to navigate the dynamic healthcare landscape, its evolving product pipeline and strategic market positioning are pivotal in shaping its long-term growth trajectory and financial performance.
